BioSpace News Archive

Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the pricing of its previously announced underwritten public offering of 14,000,000 shares of its common stock at a price to the public of $5.00 per share.

Boston Scientific Corporation (NYSE: BSX) announced the pricing of concurrent offerings of 25,550,000 shares of its common stock (“Common Stock”) at a price to the public of $34.25 per share and 8,750,000 shares of its 5.50% Mandatory Convertible Preferred Stock, Series A

Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today reported financial and operating results for the first quarter ended March 31, 2020 and provided an update on recent operating developments, including the status of the previously announced LOIs

CONMED Corporation announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share, payable on July 6, 2020 to all shareholders of record as of June 15, 2020.

Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.24 billion for the second quarter ended April 30, 2020, equal to revenue reported for the second quarter of 2019 and down 1.7% on a core(1) basis.

Combined patient sales from the 34 licensed producers in New Mexico’s Medical Cannabis Program totaled $40.1 million for the first quarter of 2020, an increase of $12 million or 43% over reported patient sales in the first quarter of 2019.

Teleflex Incorporated announced that it priced its private offering of $500.0 million aggregate principal amount of 4.25% senior notes due 2028 at an issue price of 100.000%.

4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, notes that portfolio company ADC Therapeutics SA, a late clinical stage oncology-focused biotechnology company, yesterday announced the closing of its upsized initial public offering (IPO).

ContraFect Corporation announced the pricing of its underwritten public offering of 11,797,752 shares of its common stock and related warrants to purchase 8,848,314 shares of common stock with an exercise price of $4.90 per share, in exchange for consideration equating to $4.45 for one share of common stock and a warrant to purchase 0.75 shares of common stock.

Vitalant—the nation’s largest nonprofit, independent blood collector—serving patients in 40 states, has declared a critical shortage of blood as supplies have been significantly impacted by the coronavirus pandemic.